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Introduction: 5% lidocaine medicated plasters (5% LMP) have been appointed as a ﬁrst-line
treatment for post-herpetic neuralgia (PHN), while formerly used sympathetic nerve blocks
(SNBs) were recently denied their clinical efﬁcacy. The aim of this study was to compare the
results of PHN management with the use of SNBs and 5% LMP as a ﬁrst-line treatment.
Material and methods: This study was designed as a retrospective, consecutive, case-series
study. Data of 60 consecutive PHN patients with allodynia treated with the use of SNBs and
60 subsequent patients managed with 5% LMP were analyzed. Pain severity after 8 weeks
was assessed to recognize the results of the implemented therapy, with numeric rating scale
(NRS) score <3 or =3 considered a success. Additionally, the number of pain-free patients
(NRS = 0) after 8 weeks were identiﬁed in both groups and compared.
Results: The rate of failures in SNBs and 5% LMP group was similar (18.9% vs. 27.1% of poor
treatment results, respectively), with the average change in NRS of 5.88  2.41 in nerve
blocks and 5.01  1.67 in lidocaine group (p = 0.02). Signiﬁcant difference was also noted in
the rates of pain-free patients: 20 patients (34.4%) treated with SNBs and 8 (13.5%) using 5%
LMP were pain-free after 8 weeks of treatment.
Conclusion: It may be concluded that SNBs may still be considered useful in PHN manage-
ment, as it appears that in some cases this mode of treatment may offer some advantages
over 5% LMP.
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The incidence of herpes zoster (HZ) and postherpetic neuralgia
(PHN) is large enough for us to be recognized as a common
clinical problem. Herpes zoster is thought to be a result of
varicella zoster virus (VZV) reactivation, which resides in
dorsal root ganglia (DRG) until its activation, following which it
spreads peripherally causing distal neuropathy. Clinical
presentation is usually unilateral and accompanied by pain
in the affected area, which normally lasts for several days. In
some cases pain extends beyond the acute phase and healing
of skin lesions, which along with its neuropathic character is
consistent with the diagnosis of postherpetic neuralgia (PHN).
The incidence of PHN is 9–30% of HZ cases, depending on the
source cited, while 10% is probably the most likely average [1].
The management of both HZ and PHN is challenging, there are
numerous approaches suggested which aim at reducing the
time of acute phase of the disease and pain severity, as well as
the risk of PHN. The reason for various approaches proposed in
the past is obviously its complex pathophysiology, which is
still far from being clearly deﬁned, although it is now well
established that both peripheral and central mechanisms are
involved [2]. Widely recognized guidelines on the neuropathic
pain management are being published and updated, setting its
pharmacological treatment standards [3,4]. Various techni-
ques of interventional pain management have been employed
in the past to battle the pain associated with HZ and PHN,
effectiveness of which have been scrutinized and summarized
in the 2013 guidelines for interventional pain management of
neuropathic pain [5]. According to these guidelines the
sympathetic nerve blocks (SNBs) are not recommended in
the treatment of PHN. We had been using nerve blocks as the
addition to pharmacological treatment in the management of
PHN for number of years, which in 2010 was replaced by 5%
lidocaine medicated plasters (5% LMP). Since our overall
experience with SNBs had been very plausible, we decided
to analyze the available clinical data in order to compare these
two methods of PHN therapy.
2. Material and methods
The study was approved by institutional ethics committee. We
identiﬁed and reviewed medical records of 120 consecutive
PHN patients who were treated from 2008 until Feb 2014 in the
Pain Clinic, Department of Anesthesiology and Intensive Care,
Medical Center for Postgraduate Education in Warsaw, and
whose clinical picture contained allodynia. PHN was deﬁned
as the pain of typical character (constant throbbing pain or
intermittent sharp pain, and allodynia), persisting beyond the
healing of herpetic skin lesions (more than 4 weeks of the rash
onset). Regardless of earlier treatment, the similar regime of
management was proposed to all of them, which consisted of
either sympathetic nerve block (ﬁrst 60 patients with allody-
nia) or 5% lidocaine medicated plaster (subsequent 60
patients), which if not adequately effective was accompanied
ﬁrst by gabapentinoid, then antidepressant and potent opioid.
Our aim was to compare the groups of similar characteristics,
thus the number of analyzed cases of PHN treated with SNBswas determined by the number of patients in whom 5% LMP
plasters were used, which until Feb 2014 was 60. For the
purpose of unbiased analysis no further cases were added,
even if decision was made to exclude the patient.
2.1. Techniques
The method of nerve block placement was similar for the given
pain location. With the exception of lumbar epidural and
sciatic nerve blocks, the local anesthetic used was bupivacaine
2.5 mg/ml (0.25%) with epinephrine 2.5 mg/ml. For PHN of the
ﬁrst trigeminal (ophthalmic) nerve its isolated blockade with
5 ml of 0.25% bupivacaine/epinephrine was implemented.
Affected second and/or third trigeminal nerve branch, as well
as neck and upper extremity PHN were the indications for
stellate ganglion block, for which the modiﬁed blind para-
tracheal approach technique as described by Carron was
employed, with 5 ml of 0.25% bupivacaine/epinephrine [6].
Chest was the most common location of the PHN. Blocks of the
corresponding intercostal nerves were placed in these cases
with the same concentration of local anesthetic. Three to ﬁve
neighboring intercostal nerves were typically blocked with
3 ml of local anesthetic solution each, along the scapular line.
Sciatic nerve block was implemented in cases where lower
extremity was affected. The series of SNBs was started at the
ﬁrst Pain Clinic visit, procedures were repeated twice a week
(Mon and Thu). Pharmacological treatment with gabapentin
and tricyclic antidepressant was added at the third visit if pain
control was not effective, which was deﬁned as Numeric
Rating Scale score >3 (NRS > 3). If no success was achieved,
after two weeks a potent opioid was introduced. SNBs were
continued until either a total of 10 blocks were done or success
achieved (NRS ≤ 3).
Similarly 5% lidocaine medicated plasters were prescribed at
the ﬁrst visit, to be applied for 12 ha day to the affected area, up
to 3 plasters at a time, with 12 h plaster-free time in 24 h. Pain
control was reassessed after a week and the same as in nerve
blocks group pharmacological treatment was added if found not
to be satisfactory (NRS > 3). Unlike SNBs, the lidocaine plasters
were continued for the whole period of 8 weeks.
Pain severity after 8 weeks of Pain Clinic care was used to
assess the management success or failure. We arbitrarily
assumed NRS < 3 or =3 as a cut-off point for therapy success,
while spectacular results (NRS 0) were recognized and
recorded separately. Statistical analysis was done with
Statistica 10 (StatSoft) software: Fisher's exact test was used
to compare the rates of treatment results in the groups
assessed and student t-test to ﬁnd the difference in mean NRS
change between them.
3. Results
A total of 120 cases were reviewed. Of 60 patients in each
group, 2 were excluded from SNBs group due to the lack of
patient's consent to nerve blocking in one case and a history of
previously ineffective series of SNBs in the other. Data
regarding one case treated with 5% lidocaine plasters were
excluded, as in this case the early onset of signiﬁcant allergic
skin reaction resulted in discontinuation of topical treatment.
70
80
90
100
(%
)
Table 1 – Patients characteristics.
SNBs 5% LMP
Age (mean  SD) 71.5  10.8 73.06  11.1
Time from HZ in months (median, range) 2.5 (2–36) 2 (2–48)
Male (n) 15 (26%) 25 (42.4%)
Female (n) 43 (74%) 34 (57.6%)
Time interval from HZ onset ≤3/3–12/≥12 months (n) 37/15/6 41/11/7
NRS at entry (mean  SD) 8.05  1.69 7.45  1.37
NRS at 8 weeks(mean  SD) 2.31  2.52 2.49  1.69
NRS change at 8 weeks (mean  SD, 95%CI) ( p = 0.02) 5.88  2.41; 5.24–6.51 5.01  1.67; 4.58–5.45
Diabetics (n) 11 9
Steroid therapy (n) 4 3
History of malignancy (n) 11 11
Aciclovir in the acute phase of HZ (n) 45 (77.5%) 37 (62.7%)
Gabapentinoids (n) 55 (94.8%) 51 (86.4%)
Tricyclic antidepressants (n) 31 (53.4%) 42 (71.2%)
n – number of patients.
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shown, both groups were similar in terms of their age, male/
female ratio, duration of pain and mean pain severity at the
beginning of Pain Clinic care. Areas affected are summarized
in Table 2. The review of medical notes have shown that the
rate of conditions which are known to affect the immune
system and thus facilitate HZ occurrence was not different in
both groups assessed (diabetes, steroid therapy, history of
malignancy, renal failure). After 8 weeks of treatment in 11 out
of 58 patients (18.9%) treated with nerve blocks poor treatment
results were noted, while in 5% lidocaine plasters patients the
rate of failures was slightly higher, as 16 out of 59 (27.1%)
reported pain severity >3 in NRS (Fig. 1). The difference was not
statistically signiﬁcant (two-tailed Fisher's exact test p = 0.38).
The rates of pain-free patients (NRS = 0) after 8 weeks of
treatment was found to be signiﬁcantly different: n = 20 (34.4%)
in SNBs and n = 8 (13.5%) in 5% lidocaine group (p < 0.01)
(Fig. 2). A total of 13 patients has had their symptoms for more
than 12 months before the beginning of Pain Clinic treatment:
n = 6 in SNB group and n = 7 in LMP group. Although most of the
pain-free patients in the former group has had their symptoms
for no more than 3 months (n = 14), ﬁve of them for 3–6 months
and one patient for more than a year (18 months). In contrast,
all of the 8 patients with NRS = 0 after 8 weeks of treatment
with 5% lidocaine plasters have had the duration of symptoms
for no more than 3 months. When treatment effectiveness was
considered as deﬁned by the change in NRS score, 9 patients in
both groups reported NRS change of less than 3 points in NRS.
The comparison of mean NRS change in the groups assessed is
presented in Fig. 3. Mean change in NRS score in SNBs groupTable 2 – Area affected. Data given as number of cases.
SNBs 5% LMP
1st branch of trigeminal nerve 9 2
Head and neck (2nd and 3rd
branch of trigeminal nerve)
3 10
Upper extremity 10 5
Thorax 32 38
Lower extremity 4 4was signiﬁcantly greater than that of 5% LMP group (5.88
 2.41, 95% CI 5.24–6.51 vs. 5.01  1.67, 95% CI 4.58–5.45,
p = 0.02). Of pain-free patients at 8 weeks (NRS = 0), 9 out of 20
in SNBs group had their pain severity at NRS 9 (2 patients) and
NRS 10 (7 patients) at the study entry. Only one of NRS = 0
patients after LMP treatment have started the Pain Clinic
treatment with NRS = 9, none with NRS = 10. Apart from one
case of major allergic reaction to lidocaine plaster, no other
relevant side effects of the nerve blocks and lidocaine plasters
were noted. In one LMP case some transient redness was
reported and described as being ‘‘annoying’’, but did not result
in discontinuation of the treatment. Four patients in SNBs and
one in LMP group complained of mild vertigo after gabapentin
was introduced, which resolved after it was changed to
pregabalin.
4. Discussion
This analysis presents the outcomes of PHN management with
two treatment strategies, of which one is validated by recently
published guidelines and the other might be considered
conservative, as its use was never supported by the results
of randomized controlled trials which would allow some0
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Fig. 1 – Success rate (NRS < 3 or =3) after 8 weeks of
treatment ( p = 0.38).
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Fig. 2 – Pain-free patients (NRS = 0) after 8 weeks of
treatment (p < 0.01).
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action are directed against peripheral component of neuro-
pathic pain – when the damage of afferent nociceptors results
in marked alodynia. Mechanisms by which sympathetic
system might be involved in neuropathic pain pathogenesis
are thought to include direct, pathological links between
somatic afferent and postganglionic autonomic nerves that
stem from abnormal nerve ﬁbers sprouting in the area of
neuronal damage [7], and may be mediated by noradrenaline
[8]. The SNBs use for HZ – related pain dates back to as early as
1938, when Rosenak reported procaine use in the treatment of
the acute phase of HZ [9]. Since then two more indications for
nerve blocks in conditions related to VZV infection have been
described–prevention of PHN and pain relief in established
PHN, all of which have recently come under scrutiny.
Pathomechanism of its beneﬁcial effect appears not to be
well understood and yet clariﬁed. Although some reasonable
rationale behind sympathetic blockade within the course of HZ
has been reported, it does not provide explanation for its
beneﬁt in already established neuralgia [10]. Literature data
regarding the efﬁcacy of nerve blocks in the acute phase of HZ
is much more prominent than data in support of its use in PHN
management [10,11].
After early reports by Colding [12,13], clinical reports were
limited to retrospective analyses, case series and case reports,
which suggested beneﬁcial but mostly short-lived effect of
SNBs in cases where routine approach was not effective.
Although used by many pain specialists, nerve blocking in
PHN have not earned enough credit to become a recom-
mended strategy in most recently published guidelines forN
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Fig. 3 – NRS change in the groups assessed (p = 0.02).interventional management of neuropathic pain [5]. Quite the
contrary–it is recommended not to use them for PHN. Our long
standing experience with nerve blocks and PHN was plausible,
but introduction of topical lidocaine in the form of 5% LMP and
subsequent recommendations for neuropathic pain manage-
ment have brought an end to its use.
Topical preparations of lidocaine on the other hand, being
superﬁcially active with only minimal systemic absorption,
have proved to be helpful in reducing peripheral neuropathic
pain symptoms, including PHN. They are deprived of relevant
side effects associated with the use of potent systemic drugs
used for neuropathic pain management, like dizziness and
somnolence. The efﬁcacy of 5% lidocaine plasters for PHN
management have been assessed in randomized, controlled
trials, as well as in open-label trials, most of which were
subsequently summarized in meta-analyses, where their
usefulness was conﬁrmed [14,15]. In a systematic review of
5% LMP vs. other treatments for PHN Wolff et al. have
identiﬁed two trials comparing the efﬁcacy of 5% LMP vs.
placebo and one assessing LMP vs. pregabalin [15]. Lidocaine
plasters were found to be more effective than placebo.
Pregabalin at the titrated doses was found to be less effective
after 4 weeks of treatment than LMP when the success was
deﬁned as the mean change in NRS ≥ 2 or an absolute NRS < 4
or =4. Nevertheless, after thorough analysis of available data
on 5% LMP vs. placebo and other modes of treatment, it was
concluded that further research in this area is warranted to
allow for greater number of cases to be included in systematic
reviews and analyses, as the number of good quality studies is
still small. Also, there is a marked number of limitations
reported that may affect their value. In the study by Binder
et al. [16], where LMP was reported to be more efﬁcacious than
placebo, the concomitant therapy was allowed, taken by 60%
of patients who have originally entered the study, and
described as being mostly anticonvulsants, while more
speciﬁc description is lacking [16]. Similarly, the time from
the symptoms onset is usually difﬁcult to standardize.
Although good clinical effect of PHN management was
equally frequent in our LMP and SNBs patients, the rate of
spectacular results in SNBs group was signiﬁcantly higher. It
appears that in some patients peripheral nerve blocking
resulting in the interruption of sympathetic signals to the
affected area may effect in more spectacular pain relief than
that provided by topically applied lidocaine. The fact that the
duration of pain in most of the pain-free patients in SNBs
group and none in LMP was more than 3 months may point to
the vascular nature of the pathophysiological background
behind this phenomenon. Considering the theory by Winnie
and Hartwell [10], it may be hypothesized that long-lasting
ischemia leads to irreversible damage to cutaneous nerve
endings, which are therefore less susceptible to superﬁcially
active lidocaine preparations, while SNBs' target is located
more proximally and effects in decreased noradrenaline
release from sympathetic nerve endings. Compliant with
the theory of noradrenaline-mediated link between postgan-
glionic sympathetic ﬁbers and pain afferents (chemical
coupling and/or abnormal a-adrenoreceptors activation in
PHN pain), this should decrease the PHN pain [7,8]. This theory
could obviously be challenged by data pointing to some other
than sodium channel blocking actions of topical lidocaine in
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the skin is deprived of nociceptors [17]. Nevertheless, the
difference in spectacular results is signiﬁcant. It may be argued
that our results are in contrast with widely cited early reports
by Colding, dated back to nineteen sixties and seventies,
where SNBs provided signiﬁcant but short-lived PHN pain
relief [12,13]. However, it has to be kept in mind that the
repertoire of pharmacological therapy was very limited at the
time these reports were published. In current studies most of
PHN patients take at least one of the drugs with proven
effectiveness in neuropathic pain. Almost 95% of our patients
in SNBs and 86% in 5% LMP group have taken antiepileptics, in
many cases tricyclic antidepressants were added as well. It
should also be stated that occasionally published case reports,
where SNBs proved to be effective after other treatments failed
to provide sufﬁcient pain control, may be in support of our
ﬁndings [18,19]. Considering their therapeutic effectiveness,
our results suggest that despite previous criticism sympathetic
(stellate ganglion) block as well as peripheral nerve (i.e. sciatic
nerve, intercostal nerve) block might be of clinical value and,
as such, still constitute options worth considering in allody-
nia-affected PHN cases.
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